Sandoz Receives European Commission Approval for Wyost® and Jubbonti®, the First and Only Biosimilars of Denosumab in Europe

 Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia® EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and quality Approved for treatment of cancer-related [...]